Stein D.J., Khoo J.P., Van Ameringen D.M., Hoschl C., Ahokas A., Bauer M., Bitter I., Jarema M., Mosolov S., Vavrusova L., Picarel-Blanchot F., Matharan S., Olivier V.Stein D.J.Stein D.J., Khoo J.P., Van Ameringen D.M., Hoschl C., Ahokas A., Bauer M., Bitter I., Jarema M., Mosolov S., Vavrusova L., Picarel-Blanchot F., Matharan S., Olivier V., Khoo J.P.Stein D.J., Khoo J.P., Van Ameringen D.M., Hoschl C., Ahokas A., Bauer M., Bitter I., Jarema M., Mosolov S., Vavrusova L., Picarel-Blanchot F., Matharan S., Olivier V., Van Ameringen D.M. et al. Efficacy and safety of agomelatine 25-50 mg/day versus escitalopram 10-20 mg/day in severe generalized anxiety disorder // European Neuropsychopharmacology. 2017. Vol. 27. № 4. P. S1003.

Ключевые слова: agomelatine - escitalopram - anxiety disorder - -

Krasnov V.N.Krasnov V.N.Krasnov V.N.Krasnov V.N. The generalized anxiety disorder and major depression over time // Diagnostic Issues in Depression and Generalized Anxiety Disorder: monograph / Eds D. Goldberg et al. Eds D. Goldberg et al.. Arlington: American Psychiatric Association, 2010. P. 171-177.

Ключевые слова: psychiatry - depression - anxiety disorder - mental health -